GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
SAN CARLOS, Calif., May 03, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2018 financial and operating results on Thursday, May 10, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.
In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 2995797. The live webcast can be accessed under “News & Events” in the “Investors” section of the Company’s website at http://www.iovance.com/ or you may use the link: https://edge.media-server.com/m6/p/ouykqu6a.
A replay of the call will be available from May 10, 2018 at 7:30 p.m. ET to May 17, 2018 at 8:30 p.m. ET. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 2995797. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics’ website at http://www.iovance.com/.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.
Investor Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Evan Smith
FTI Consulting
212-850-5622
[email protected]
